A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective
[EN] SIDE-CHAIN MODIFIED ERGOSTEROL AND STIGMASTEROL DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'ERGOSTÉROL ET DE STIGMASTÉROL MODIFIÉS PAR CHAÎNE LATÉRALE EN TANT QUE MODULATEURS DU RÉCEPTEUR HÉPATIQUE X
申请人:OSPEDALE SAN RAFFAELE SRL
公开号:WO2019021122A3
公开(公告)日:2019-03-07
SIDE-CHAIN MODIFIED ERGOSTEROL AND STIGMASTEROL DERIVATIVES AS LIVER X RECEPTOR MODULATORS
申请人:Ospedale San Raffaele srl
公开号:US20200157135A1
公开(公告)日:2020-05-21
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune diseases.
Shul'man, A. I.; Mikhailova, N. P.; Viktorovskii, I. V., Journal of general chemistry of the USSR, 1988, vol. 58, # 1, p. 191 - 199
作者:Shul'man, A. I.、Mikhailova, N. P.、Viktorovskii, I. V.、V'yunov, K. A.